期刊文献+
共找到2篇文章
< 1 >
每页显示 20 50 100
Association between large artery atherosclerosis and cerebral microbleeds:a systematic review and meta-analysis 被引量:14
1
作者 Lingling Ding yuehui hong Bin Peng 《Stroke & Vascular Neurology》 SCIE 2017年第1期7-14,共8页
Objective:The aim of this systematic review and meta-analysis was to provide evidence that biomarkers of large artery atherosclerosis,including arterial stenosis and greater carotid intima-media thickness(cIMT),may se... Objective:The aim of this systematic review and meta-analysis was to provide evidence that biomarkers of large artery atherosclerosis,including arterial stenosis and greater carotid intima-media thickness(cIMT),may serve as clinical markers of subclinical haemorrhage-prone cerebral small vessel disease,reflected by cerebral microbleeds(CMBs).Methods:We searched PubMed,MEDLINE,Web of Science,EMBASE and the Cochrane Library to identify relevant studies published before 1 July 2016.The association between arterial stenosis and CMBs was estimated by the OR and 95%CI.The association of cIMT and CMBs was calculated using the standardised mean difference(SMD).Heterogeneity and publication bias were explored.Results:8 studies including a total of 7160 participants were pooled in the meta-analysis.6 of the included studies were cross-sectional,except that 2 were prospective.We found a significant association between arterial stenosis>50%and the presence of CMBs(OR 1.95,95%CI 1.13 to 3.36,I2=56.1%).A fixed-effects model suggested that patients with CMBs were more likely to have a greater cIMT(SMD 0.20,95%CI 0.11 to 0.28,I2=24.7%).Conclusions:This systematic review and metaanalysis found that there is a relationship between large artery atherosclerosis and CMBs.Future studies are needed to confirm the impact of atherosclerosis on the CMBs,which may have potential therapeutic implications. 展开更多
关键词 ATHEROSCLEROSIS CEREBRAL STENOSIS
原文传递
脑淀粉样血管病合并易栓状态的临床治疗决策
2
作者 周雅萍 洪月慧 +3 位作者 苏宁 刘暴 朱铁楠 倪俊 《中华脑血管病杂志(电子版)》 2024年第4期338-344,共7页
目的回顾并报道1例散发性脑淀粉样血管病(CAA)合并JAK2基因突变致原发性血小板增多症(ET)及下肢深静脉血栓形成(DVT)患者的临床诊治过程,为此类患者临床抗栓决策提供参考。方法总结2024年2月就诊于北京协和医院神经科的1例CAA合并JAK2... 目的回顾并报道1例散发性脑淀粉样血管病(CAA)合并JAK2基因突变致原发性血小板增多症(ET)及下肢深静脉血栓形成(DVT)患者的临床诊治过程,为此类患者临床抗栓决策提供参考。方法总结2024年2月就诊于北京协和医院神经科的1例CAA合并JAK2基因突变致ET及下肢DVT患者的临床资料及多学科协助的诊疗过程,同时复习国内外有关CAA合并ET的相关病例报道,总结此类患者的临床特点、治疗矛盾、抗栓决策及预后。结果本例患者为74岁女性,临床主要表现为慢性进行性认知功能下降,头磁共振成像(MRI)提示多发局限脑叶微出血、皮层表浅含铁血黄素沉积、多发脑白质高信号及腔隙等,排除其他病因,根据Boston 2.0诊断标准,符合很可能的CAA(Probable CAA)诊断,自发性脑出血风险较高。同时,患者合并JAK2基因突变相关ET及进展性DVT,具有明确的抗凝指征,治疗存在矛盾。经神经科、血液科及血管外科多学科讨论评估本患者出血和血栓风险,权衡利弊,给予羟基脲降血小板治疗的基础上,加用预防剂量利伐沙班(10 mg/d)口服治疗,同时积极控制心血管危险因素。出院3个月随访患者下肢DVT好转,且未发生出血,提示该方案安全有效。复习文献,仅国外报道1例CAA合并ET病例,该例患者出血风险高于血栓风险,治疗以预防出血为主,停用抗栓治疗。结论当CAA合并高凝/易栓性疾病时,需权衡出血及血栓风险,进行个体化抗栓决策,同时密切随诊,动态评估、调整治疗方案。对于CAA合并ET及DVT的患者,若近期内血栓风险较高而出血风险相对较低,可在降低血小板数量及控制心血管危险因素的基础上使用预防量抗凝治疗,药物选择以新型口服抗凝药为首选,动态评估药物疗效和安全性并随时调整剂量。 展开更多
关键词 脑淀粉样血管病 原发性血小板增多症 深静脉血栓 抗凝治疗 出血风险
原文传递
上一页 1 下一页 到第
使用帮助 返回顶部